Female Health Company (The) (VERU) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Female Health Company (The) (NASDAQ:VERU) in a research report released on Wednesday. The brokerage currently has a $5.00 price target on the stock.

VERU has been the topic of a number of other research reports. ValuEngine upgraded Female Health Company (The) from a sell rating to a hold rating in a research report on Thursday, August 31st. Zacks Investment Research upgraded Female Health Company (The) from a hold rating to a buy rating and set a $2.50 target price on the stock in a research report on Wednesday, September 27th. Finally, Rodman & Renshaw began coverage on Female Health Company (The) in a research report on Wednesday, July 26th. They issued a buy rating and a $5.00 target price on the stock.

Shares of Female Health Company (VERU) traded up 4.02% during trading on Wednesday, reaching $2.07. The company’s stock had a trading volume of 230,534 shares. Female Health Company has a 1-year low of $0.72 and a 1-year high of $2.15. The stock has a 50 day moving average of $1.38 and a 200-day moving average of $1.14.

Female Health Company (The) (NASDAQ:VERU) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.03) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.05. Female Health Company (The) had a negative return on equity of 16.78% and a negative net margin of 42.02%. The firm had revenue of $4.31 million for the quarter, compared to the consensus estimate of $2.20 million. On average, analysts forecast that Female Health Company will post ($0.17) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Female Health Company (The) (VERU) Stock Rating Reaffirmed by HC Wainwright” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://transcriptdaily.com/2017/10/08/female-health-company-the-veru-stock-rating-reaffirmed-by-hc-wainwright.html.

In other Female Health Company (The) news, Director Harry Fisch bought 34,250 shares of Female Health Company (The) stock in a transaction on Wednesday, September 13th. The shares were bought at an average price of $1.51 per share, for a total transaction of $51,717.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mitchell Shuster Steiner bought 100,000 shares of Female Health Company (The) stock in a transaction on Friday, September 15th. The stock was acquired at an average price of $1.63 per share, for a total transaction of $163,000.00. Following the transaction, the insider now directly owns 7,764,767 shares of the company’s stock, valued at $12,656,570.21. The disclosure for this purchase can be found here. Insiders acquired 146,975 shares of company stock worth $234,279 in the last 90 days. Company insiders own 10.90% of the company’s stock.

Female Health Company (The) Company Profile

Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.

Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply